Incyte Corp

NASDAQ:INCYUnited States

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.

Contact Information

Headquarters

1801 Augustine Cut-OffWILMINGTON, DE, United States 19803

Phone

302-498-6700

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer

Herve Hoppenot

President and Head - Research and Development

Pablo Cagnoni

Chief Financial Officer, Executive Vice President

Christiana Stamoulis

Executive Vice President, General Counsel, Corporate Secretary

Sheila Denton

Executive Vice President, General Manager, Europe

Jonathan Dickinson